Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod Alfa in Mild to Moderate Pemphigus
NCT03334058Phase 2Completed
- Sponsor
- argenx
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Antibody Fragments
- Countries
- 5
01
Overview
A Phase 2 trial of efgartigimod alfa in pemphigus vulgaris (PV), pemphigus foliaceus (PF), sponsored by argenx. Started Oct 2017; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT03334058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334058.